Seo Soo Hyun, Park Young Suk, Nam Soo Kyung, Lee Hye Seung, Park Do Joong, Park Kyoung Un
Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Korean J Clin Oncol. 2023 Dec;19(2):45-51. doi: 10.14216/kjco.23009. Epub 2023 Dec 31.
Combined analysis of the variant composition of circulating tumor DNA (ctDNA) from cell-free plasma and DNA from tumor tissue could provide insight into the implications of the genetic alterations responsible for the intratumoral and intertumoral heterogeneity of gastric cancer. We aimed to evaluate the usefulness of this approach in these patients.
Cell-free plasma and formalin-fixed paraffin-embedded tumor tissue samples from 46 patients with gastric cancer were examined. Targeted deep sequencing was performed using a commercially available kit.
The cell-free DNA (cfDNA) concentration was higher in stage II-IV versus stage I patients and in larger versus smaller tumors. Only 12 of the 36 (33.3%) alterations in the tumor tissue samples were in concordance with those in the ctDNA samples. Two variants were in concordance in stage I samples and 10 in stage II-IV samples. Actionable variants that were detected in concordance were in the stage II-IV samples. Preoperative ctDNA positivity of actionable variants was significantly associated with cfDNA concentration, lymphatic invasion, N stage, and TNM stage. Cancer recurrence was significantly associated with tumor size, lymphatic/vascular invasion, TNM stage, and ctDNA-tumor tissue variant concordance.
Preoperative ctDNA genetic analysis using a multigene panel offers substantial clinical benefits when performed in conjunction with targeted deep sequencing of tumor tissue. Concordance between preoperative ctDNA and tumor tissue mutations may serve as a prognostic indicator in patients with gastric cancer.
对来自游离血浆的循环肿瘤DNA(ctDNA)和肿瘤组织DNA的变异组成进行联合分析,有助于深入了解导致胃癌肿瘤内和肿瘤间异质性的基因改变的影响。我们旨在评估这种方法对这些患者的实用性。
对46例胃癌患者的游离血浆和福尔马林固定石蜡包埋肿瘤组织样本进行检测。使用市售试剂盒进行靶向深度测序。
II-IV期患者的游离DNA(cfDNA)浓度高于I期患者,较大肿瘤患者的cfDNA浓度高于较小肿瘤患者。肿瘤组织样本中的36种改变中,只有12种(33.3%)与ctDNA样本中的改变一致。I期样本中有2种变异一致,II-IV期样本中有10种一致。一致检测到的可操作变异存在于II-IV期样本中。可操作变异的术前ctDNA阳性与cfDNA浓度、淋巴浸润、N分期和TNM分期显著相关。癌症复发与肿瘤大小、淋巴/血管浸润、TNM分期以及ctDNA-肿瘤组织变异一致性显著相关。
术前使用多基因检测板进行ctDNA基因分析,并与肿瘤组织的靶向深度测序结合使用,可带来显著的临床益处。术前ctDNA与肿瘤组织突变之间的一致性可能作为胃癌患者的预后指标。